Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Correction 03 June 2020: In the original version of this article, Timothy Yu’s comment that "academics are not well positioned to lead the charge for n-of-one therapies" is inaccurate. Yu thinks that academic medical centers will play a key role in developing n-of-one therapies, although they aren’t positioned to scale up yet. Also, the cost Yu mentions for oligonucleotide synthesis refers to research grade oligonucleotides, not clinical grade ones, which are more expensive. The text has been corrected to address these errors.
An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.